CB2 Receptor Involvement in the Treatment of Substance Use Disorders

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Nov 27

PMID 34827554

Citations 9

Authors

Francisco Navarrete

Maria S Garcia-Gutierrez

Ani Gasparyan

Daniela Navarro

Jorge Manzanares

Affiliations

Soon will be listed here.

Abstract

The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine. In addition, the discovery of CB2r in brain areas that are part of the reward system supports the relevance of CB2r in the field of addiction. Interestingly, animal studies support that the CB2r regulates anxiety and depression behavioral traits. Due to its frequent comorbidity with neuropsychiatric disorders, these pharmacological actions may be of great interest in managing SUD. Preliminary clinical trials are focused on exploring the therapeutic potential of modulating CB2r in treating addictive disorders. These promising results support the development of new pharmacological tools regulating the CB2r that may help to increase the therapeutic success in the management of SUD.

Citing Articles

The cannabinoid CB agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats.

Guenther K, Wirt J, Oliva I, Saberi S, Crystal J, Hohmann A Neuropharmacology. 2024; 265():110257.

PMID: 39644993 PMC: 11729772. DOI: 10.1016/j.neuropharm.2024.110257.

Promising immunomodulators for management of substance and alcohol use disorders.

Acuna A, Park C, Leyrer-Jackson J, Olive M Expert Opin Pharmacother. 2024; 25(7):867-884.

PMID: 38803314 PMC: 11216154. DOI: 10.1080/14656566.2024.2360653.

Alcohol induced behavioral and immune perturbations are attenuated by activation of CB2 cannabinoid receptors.

Roberts A, Christian M, Dilone L, Nelson N, Endrino M, Kneebone A Adv Drug Alcohol Res. 2024; 3:11602.

PMID: 38389814 PMC: 10880753. DOI: 10.3389/adar.2023.11602.

Role of the CB2 Cannabinoid Receptor in the Regulation of Food Intake: A Systematic Review.

Rodriguez-Serrano L, Chavez-Hernandez M Int J Mol Sci. 2023; 24(24).

PMID: 38139344 PMC: 10743788. DOI: 10.3390/ijms242417516.

Effects of exercise of different intensities on withdrawal symptoms among people with substance use disorder: a systematic review and meta-analysis.

Li H, Su W, Cai J, Zhao L, Li Y Front Physiol. 2023; 14:1126777.

PMID: 37234417 PMC: 10208401. DOI: 10.3389/fphys.2023.1126777.

References

Navarrete F, Perez-Ortiz J, Manzanares J . Cannabinoid CB₂ receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice. Br J Pharmacol. 2011; 165(1):260-73. PMC: 3252982. DOI: 10.1111/j.1476-5381.2011.01542.x. View

Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M . Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009; 89(1):309-80. DOI: 10.1152/physrev.00019.2008. View

Gong J, Onaivi E, Ishiguro H, Liu Q, Tagliaferro P, Brusco A . Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006; 1071(1):10-23. DOI: 10.1016/j.brainres.2005.11.035. View

Matsuda L, Lolait S, Brownstein M, Young A, Bonner T . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284):561-4. DOI: 10.1038/346561a0. View

Busquets-Garcia A, Bains J, Marsicano G . CB Receptor Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. 2017; 43(1):4-20. PMC: 5719111. DOI: 10.1038/npp.2017.206. View

Guzman M, Sanchez C, Galve-Roperh I . Control of the cell survival/death decision by cannabinoids. J Mol Med (Berl). 2001; 78(11):613-25. DOI: 10.1007/s001090000177. View

Alger B, Kim J . Supply and demand for endocannabinoids. Trends Neurosci. 2011; 34(6):304-15. PMC: 3106144. DOI: 10.1016/j.tins.2011.03.003. View

Garcia-Cabrerizo R, Garcia-Fuster M . Opposite regulation of cannabinoid CB1 and CB2 receptors in the prefrontal cortex of rats treated with cocaine during adolescence. Neurosci Lett. 2016; 615:60-5. DOI: 10.1016/j.neulet.2016.01.018. View

Pradier B, Erxlebe E, Markert A, Racz I . Interaction of cannabinoid receptor 2 and social environment modulates chronic alcohol consumption. Behav Brain Res. 2015; 287:163-71. DOI: 10.1016/j.bbr.2015.03.051. View

10.

Hu B, Doods H, Treede R, Ceci A . Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain. 2009; 143(3):206-212. DOI: 10.1016/j.pain.2009.02.018. View

11.

Ishiguro H, Iwasaki S, Teasenfitz L, Higuchi S, Horiuchi Y, Saito T . Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J. 2006; 7(6):380-5. DOI: 10.1038/sj.tpj.6500431. View

12.

George D, Herion D, Jones C, Phillips M, Hersh J, Hill D . Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl). 2009; 208(1):37-44. PMC: 2963590. DOI: 10.1007/s00213-009-1704-3. View

13.

Yang P, Wang L, Xie X . Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem. 2012; 4(2):187-204. PMC: 3501202. DOI: 10.4155/fmc.11.179. View

14.

Filip M, Golda A, Zaniewska M, McCreary A, Nowak E, Kolasiewicz W . Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol Rep. 2007; 58(6):806-19. View

15.

Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomo M . Identification of the First Synthetic Allosteric Modulator of the CB Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. J Med Chem. 2018; 62(1):276-287. DOI: 10.1021/acs.jmedchem.8b00368. View

16.

TSOU K, Brown S, Mackie K, Walker J . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2):393-411. DOI: 10.1016/s0306-4522(97)00436-3. View

17.

Yiangou Y, Facer P, Durrenberger P, Chessell I, Naylor A, Bountra C . COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006; 6:12. PMC: 1413551. DOI: 10.1186/1471-2377-6-12. View

18.

Garcia-Gutierrez M, Manzanares J . Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol. 2010; 25(1):111-20. DOI: 10.1177/0269881110379507. View

19.

Benito C, Tolon R, Pazos M, Nunez E, Castillo A, Romero J . Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2007; 153(2):277-85. PMC: 2219537. DOI: 10.1038/sj.bjp.0707505. View

20.

Morales M, Bonci A . Getting to the core of addiction: Hooking CB2 receptor into drug abuse?. Nat Med. 2012; 18(4):504-5. PMC: 9479678. DOI: 10.1038/nm.2722. View